Skip to content

Introducing Joenja – the first targeted treatment for APDS

Click through the topics below for more information relating to Joenja, including clinical data and considerations for prescribers.

What is Joenja?

Joenja is the first and only disease-specific medicine that is designed to target the underlying immune defect in APDS, binding to the active site of the PI3Kδ enzyme.1–4 Joenja is selective for the delta isoform of PI3K, over the alpha, beta and gamma isoforms.3 Through this specificity Joenja attenuates its activity.1,3 This results in decreased PIP3 production and reduced downstream AKT signalling, reducing mTOR activity and restoring FOXO activity.1,3 This rebalances the survival, differentiation, proliferation, growth and migration of B and T cells, addressing the cause of the immune deficiency and immune dysregulation components of the disease.1–3

Joenja tablets are yellow and oval shaped. Each tablet contains 70 mg of leniolisib. Each pack contains 1 bottle with 60 Joenja tablets.

The efficacy and safety of Joenja have been investigated in multiple clinical trials, providing up to 5 years of data across Phase 2, Phase 3 and open-label extension studies. These trials provided data across a breadth of clinical endpoints, including 37 patients with APDS receiving Joenja for a median time of 102 weeks.2,5,6

  • Demonstrated significant reductions in lymphadenopathy and a significant increase in naïve B cells
  • Provided reductions in spleen volume
  • Provided reductions in IgM levels for patients with high IgM at baseline
  • Was generally well-tolerated
  • Resulted in less than one in four patients experiencing TRAEs, no serious TRAEs and no discontinuations

Across these trials patient experience on treatment was also studied – most patients explicitly attributed an improvement in APDS-related symptoms and HRQoL to treatment with Joenja, including improvements in work/school performance/attendance, with one in three patients attributing an improvement in overall wellbeing to treatment with Joenja.8

  • Twice-daily oral tablet, taken with or without food
  • No special instructions before or after taking Joenja

Consider Joenja for the treatment of APDS in adults and adolescent patients 12 years and older and weighing 45 kg or more.1

Diagram showing phase 3 clinical trial
Disease characteristicsJoenja

(n=21)
Placebo

(n=10)
IRT (concomitant IgG), n (%)14 (66.7)7 (70.0)
Previous rapamycin/sirolimus use, n (%)4 (19.0)3 (30.0)
Lymphoproliferation,* n (%)15 (71.4)7 (70.0)
Chronic infections, n (%)18 (85.7)7 (70.0)
Pulmonary disease, n (%)14 (66.7)8 (80.0)
*Documented clinical history of lymphoproliferation (e.g., lymphadenopathy, splenomegaly, hepatomegaly) varied.
Diagram showing change from baseline in naive B cells at Day 85
Adapted from Rao VK, et al. 2023.5
Least squares mean of the change from baseline at Day 85 in the percentage of naïve B cells (CD19+CD27-CD10-) out of total B CD19+ cells. Error bars are SEM.
 *Two patients from each treatment arm were excluded due to protocol deviations and only participants with <48% naïve B cells at baseline were included in the primary analysis (n=13).5

An increase in the proportion of naïve B cells is indicative of an improvement in immune deficiency in APDS with Joenja.5

Diagram showing spleen volumes
Adapted from Rao VK, et al. 2023.5
Individual spleen volumes (Joenja, n=20; placebo, n=9). The grey box indicates the reference range for adults. All participants from the safety analysis set with measurements are included.

Reduction in spleen size suggests Joenja has a positive effect on immune dysregulation seen in patients with APDS.5

These included including liver size, B-cell populations, T-cell populations, serum immunoglobulin levels, cytokines, viral burden (EBV/CMV) and cytopenias.5 Data from exploratory endpoints are not powered for definitive conclusions and should be interpreted with caution. Details of the exploratory endpoints can be found in Rao VK, et al. Blood. 2023;141(9):971–983.

Diagram showing percentage of patients reporting adverse events
Adapted from Rao VK, et al. 2023.5

Joenja was generally well tolerated, with no AEs leading to discontinuation. The most common AEs for patients treated with Joenja were headache (n=5/21; 23.8%) and sinusitis (n=4/21; 19.0%).1,5

Diagram showing AEs reported during open-label extension
Adapted from Rao VK, et al. 2024.7

The median exposure to Joenja was 4.3 years, with six patients receiving treatment for ~6 years.7,10 The most common AEs were otitis media (n=3) and upper respiratory tract infection (n=3).7

Chart showing rate of total infections

Per additional year of Joenja therapy, overall infection rates decreased by 25%, which was a nominally significant change (one-sided p-value 0.0005).10

These included serum IgM levels, use of anti-infective co-medications such as IRT and antibiotics, reduction of lymphoproliferation as assessed via changes in spleen volume and lymph node size, B- and T-cell immunophenotyping, cytokine and chemokine profiles, CMV and EBV viremia.6 Data from exploratory endpoints are not powered for definitive conclusions and should be interpreted with caution. Details of the exploratory endpoints can be found in Rao VK, et al. Blood Adv. 2024;8(12):3092–3108 and Rao VK, et al. Poster presented at the International Primary Immunodeficiencies congress, 5–7 November 2025, Prague, Czech Republic.